MESOBLAST LTD
MEOBF
|
$0.1667
314.16%
10K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-72.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (900.0% volume)
Earnings Calendar:
Market Cap: $ 215,452,372
http://www.mesoblast.com
Sec Filling | Patents | n/a employees
(AU) Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
t-cell stem cell ceiling cardiovascular
add to watch list Paper trade email alert is off
Intellipharmaceutics International Inc.
IPCIF
|
$0.06
100
|
Health Technology
(0.0% 1d) (20.0% 1m) (9.1% 1y) (0.0% 2d) (-50.0% 3d) (-14.3% 7d) (-96.45% volume)
Earnings Calendar:
Market Cap: $ 1,985,560
http://www.intellipharmaceutics.com
Sec Filling | Patents | n/a employees
(CA) Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of pharmaceuticals in the areas of neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The company was founded by Isa Odidi and Amina Odidi in 1998 and is headquartered in Toronto, Canada.
gastrointestinal urea diabetic diabetes cardiovascular
add to watch list Paper trade email alert is off
MEDICURE INC
MCUJF
|
$0.6797
130
|
Health Technology
(0.0% 1d) (-22.5% 1m) (-28.4% 1y) (0.0% 2d) (-5.6% 3d) (-8.1% 7d) (-98.6% volume)
Earnings Calendar:
Market Cap: $ 7,093,562
http://www.medicure.com
Sec Filling | Patents | n/a employees
(CA) Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. It focuses on the marketing and distribution of its acute care cardiovascular drug, AGGRASTAT; ZYPITAMAG (pitavastatin) tablets and the ReDS device in the United States. The company was founded by Albert D. Friesen on September 15, 1997 and is headquartered in Winnipeg, Canada.
cardiovascular
add to watch list Paper trade email alert is off
Renovacor, Inc.
RCOR | $3.2 0.0%
|
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-55.26% volume)
Earnings Calendar:
Market Cap: $ 55,262,128
https://renovacor.com
Sec Filling | Patents | 2 employees
Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor’s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
gene therapies urea cardiovascular
add to watch list Paper trade email alert is off
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVJF
|
News
|
$12.37
-24.22%
380
|
Health Technology
(0.0% 1d) (0.0% 1m) (48.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (83.09% volume)
Earnings Calendar:
Market Cap: $ 14,739,472,016
http://www.teva.co.il
Sec Filling | Patents | n/a employees
(IL) Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
cancer infectious disease pain relief israel cardiovascular
add to watch list Paper trade email alert is off
Cardiovascular Systems, Inc.
CSII
|
$20.0
-0.05%
400K
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (22.61% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 843,960,960
http://www.csi360.com
Sec Filling | Patents | 779 employees
(US) Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The firm's products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 1989 and is headquartered in St. Paul, MN.
cardiovascular
add to watch list Paper trade email alert is off
Ambrx Biopharma Inc - ADR
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (187.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (117.58% volume)
Earnings Calendar:
Market Cap: $ 1,768,206,832
https://ambrx.com
Sec Filling | Patents | n/a employees
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.
urea antibody genetic cardiovascular optical metabolic
add to watch list Paper trade email alert is off
Verve Therapeutics Inc
VERV | $6.85 -0.44% 110K
|
Professional, Scientific, and T...
(0.0% 1d) (-47.7% 1m) (-56.2% 1y) (0.0% 2d) (-0.4% 3d) (3.6% 7d) (6.15% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 572,792,061
https://www.vervetx.com
Sec Filling | Patents | 63 employees
Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.
genetic cardiovascular
add to watch list Paper trade email alert is off
Sanofi
SNYNF
|
News
|
$94.25
480
|
Health Technology
(0.0% 1d) (-5.7% 1m) (-16.6% 1y) (0.0% 2d) (0.0% 3d) (1.7% 7d) (-99.92% volume)
Earnings Calendar:
Market Cap: $ 120,636,938,854
http://www.sanofi.com
Sec Filling | Patents | n/a employees
(FR) Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
vaccine diabetic diabetes cardiovascular
add to watch list Paper trade email alert is off
Endo International plc
ENDP
|
News
|
$0.2926
-9.6%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-5.0% 3d) (0.0% 7d) (97.63% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 68,802,809
http://www.endo.com
Sec Filling | Patents | 3172 employees
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.
cardiovascular women health nervous system women brands msa injection
add to watch list Paper trade email alert is off
China Pharma Holdings, Inc.
CPHI
|
$0.309
-2.65%
250K
|
Health Technology
(0.0% 1d) (-16.5% 1m) (-5.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (70.83% volume)
Earnings Calendar:
Market Cap: $ 4,578,411
http://www.chinapharmaholdings.com
Sec Filling | Patents | 242 employees
(China (Mainland)) China Pharma Holdings, Inc. engages in the development, manufacture, and marketing of pharmaceutical products. It caters people with cardiovascular, central nervous system, infectious, and digestive diseases. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.
cardiovascular china nervous system
add to watch list Paper trade email alert is off
ASTRAZENECA PLC
AZNCF
|
News
|
$140.3
1.5K
|
Health Technology
(0.0% 1d) (5.3% 1m) (-7.1% 1y) (0.0% 2d) (1.1% 3d) (3.0% 7d) (-58.71% volume)
Earnings Calendar:
Market Cap: $ 219,666,356,526
http://astrazeneca.com
Sec Filling | Patents | n/a employees
(GB) AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
respiratory urea metabolic cardiovascular
add to watch list Paper trade email alert is off
BioCardia, Inc.
BCDA
P
|
$0.376
6.4K
|
Health Technology
(0.0% 1d) (-6.2% 1m) (-81.0% 1y) (0.0% 2d) (2.7% 3d) (0.0% 7d) (20.84% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 10,102,188
http://www.biocardia.com
Sec Filling | Patents | 24 employees
(US) BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.
cardiovascular brands msa
add to watch list Paper trade email alert is off
Cyanotech Corporation
CYAN
|
$0.3005
700
|
Health Technology
(0.0% 1d) (3.1% 1m) (-69.1% 1y) (0.0% 2d) (0.0% 3d) (-14.3% 7d) (207.49% volume)
Earnings Calendar:
Market Cap: $ 2,087,988
http://www.cyanotech.com
Sec Filling | Patents | 95 employees
Cyanotech Corp. engages in the development and commercialization of natural products derived from microalgae. Its products include BioAstin natural astaxanthin, a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health; and Spirulina Pacifica, a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.
skin energy cardiovascular eye msa
add to watch list Paper trade email alert is off
Reviva Pharmaceuticals Holdings Inc.
RVPH
|
$3.02
-1.31%
12K
|
(0.0% 1d) (-2.5% 1m) (-54.6% 1y) (0.0% 2d) (-1.0% 3d) (1.3% 7d) (-30.27% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 84,314,051
https://revivapharma.com
Sec Filling | Patents | 5 employees
Reviva Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's primary focus is developing its lead product candidate, RP5063 (brilaroxazine), for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Reviva also intends to develop RP5063 for treating PAH and IPF. RP5063 is a serotonin, dopamine, and nicotinic receptor active compound, which has successfully completed a global Phase 2 clinical trial and has shown clinical efficacy and safety for schizophrenia and schizoaffective disorder.
urea treatment schizophrenia nervous system cardiovascular metabolic
add to watch list Paper trade email alert is off
Teva Pharmaceutical Industries Limited
TEVA
|
$13.01
1.2M
|
Health Technology
(0.0% 1d) (-7.5% 1m) (58.1% 1y) (0.0% 2d) (1.0% 3d) (1.2% 7d) (13.05% volume)
Earnings Calendar:
Market Cap: $ 14,584,111,085
http://www.teva.co.il
Sec Filling | Patents | 40039 employees
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
cardiovascular cancer infectious disease israel pain relief
add to watch list Paper trade email alert is off
Atrion Corporation
ATRI
|
$410.6
1.31%
9.9K
|
Health Technology
(0.0% 1d) (-7.3% 1m) (-37.0% 1y) (0.0% 2d) (1.4% 3d) (0.7% 7d) (28.45% volume)
Earnings Calendar:
Market Cap: $ 722,637,112
http://www.atrioncorp.com
Sec Filling | Patents | 616 employees
(US) Atrion Corp. engages in the manufacture and development of products for medical applications. It offers products fro cardiovascular, fluid delivery, and ophthalmic. It also offers contract manufacturing and kitting services; and marine and aviation inflation components. The company was founded in 1944 and is headquartered in Allen, TX.
cardiovascular marine
add to watch list Paper trade email alert is off
Taro Pharmaceutical Industries Ltd.
TARO
|
$42.225
-0.01%
2.1K
|
Health Technology
(0.0% 1d) (-0.0% 1m) (71.5% 1y) (0.0% 2d) (-0.1% 3d) (-0.0% 7d) (37.38% volume)
Earnings Calendar:
Market Cap: $ 1,587,011,044
http://www.taro.com
Sec Filling | Patents | 1464 employees
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.
cardiovascular israel neuropsychiatric
add to watch list Paper trade email alert is off
Ra Medical Systems, Inc.
RMED
|
$0.594
0.0%
78K
|
Health Technology
(0.0% 1d) (0.0% 1m) (-55.0% 1y) (0.0% 2d) (10.0% 3d) (0.0% 7d) (-40.66% volume)
Earnings Calendar:
Market Cap: $ 3,188,398
http://www.ramed.com
Sec Filling | Patents | 79 employees
(US) Ra Medical Systems, Inc. engages in the design, development, and commercialization of excimer lasers for the treatment of dermatologic and cardiovascular diseases. Its product, Pharos, is used for the treatment of difficult-to-treat, chronic diseases including psoriasis and vitiligo. It operates through the Dermatology and Vascular business segments. The company was founded by Dean Irwin and Melissa Burstein in 2002 and is headquartered in Carlsbad, CA.
cardiovascular treatment
add to watch list Paper trade email alert is off
Acasti Pharma, Inc.
ACST
|
$2.88
130
|
Health Technology
(0.0% 1d) (-15.5% 1m) (1.0% 1y) (0.0% 2d) (1.1% 3d) (0.3% 7d) (-54.73% volume)
Earnings Calendar: 2023-06-21
Market Cap: $ 27,070,284
http://www.acastipharma.com
Sec Filling | Patents | 32 employees
(CA) Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
cardiovascular
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
CZOO | $11.44 129.26% 4.6M
|
AMST | $3.4 70.0% 51M
|
Technology Services
BOF | $1.93 64.96% 55M
|
CSSE 4 | $0.23 51.02% 46M
|
Consumer Services
TROO | $1.57 44.04% 2.8M
|
Manufacturing
RILY | $30.87 42.13% 7.8M
|
Finance
LICN | $0.76 35.71% 6.2M
|
WHLM | $6.61 30.12% 400K
|
Commercial Services
MULN | News | $3.53 29.3% 4.8M
|
Information
RBBN 4 | $3.26 26.85% 1.2M
|
Electronic Technology
Last 48 Hours Insiders Buying
MEGI | $11.97 -0.08% 42K
|
|
00:30
CTRN P 29000 | $22.57 1.53% 14K
|
Retail Trade
|
22:00
CONN | $3.7 12K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.685 6.6K
|
Utilities
|
18:30
CMTV P 700 | $16.59 1K
|
Finance and Insurance
|
18:30
FNB | $13.615 -0.11% 110K
|
Finance
|
17:30
RMCF | $3.54 410
|
Consumer Non-Durables
|
20:10